Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function - Full Text View

Purpose

To compare the pharmacokinetics of Dimebon in subjects with mild and moderate hepatic impairment to subjects with normal hepatic function.
To assess the safety and tolerability of Dimebon in subjects with hepatic impairment and subjects with normal hepatic function.
To explore the pharmacokinetics of Dimebon in subjects with severely-impaired hepatic function.

Condition	Intervention	Phase
Hepatic Failure	Drug: Dimebon	Phase 1

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function

Further study details as provided by Pfizer:

Primary Outcome Measures:

Pharmacokinetics (AUC and Cmax) [ Time Frame: 1 day ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Safety (AEs, labs, ECG, vitals) [ Time Frame: 1 day ] [ Designated as safety issue: Yes ]

Enrollment:	23
Study Start Date:	February 2009
Study Completion Date:	August 2009
Primary Completion Date:	August 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Normal Healthy Volunteers	Drug: Dimebon Dimebon 5mg in healthy controls
Experimental: Mild Hepatic Impairment Mild hepatic impairment patients	Drug: Dimebon Dimebon 5mg in mild hepatic impairment patients
Experimental: Moderate hepatic Impairment Moderate Hepatic Impairment Patients	Drug: Dimebon Dimebon 5mg in moderate hepatic impairment patients
Experimental: Severe Hepatic Impairment Severe Hepatic Impairment Patients	Drug: Dimebon Dimebon 5mg in Severe Hepatic Impairment

Eligibility

Criteria

Inclusion Criteria:

Healthy (healthy is defined as the absence of clinically-relevant abnormalities identified by a detailed medical history, full physical examination, 12-lead ECG and clinical laboratory tests).
Free of any medical or surgical conditions that might significantly interfere with gastrointestinal absorption, distribution, metabolism, or excretion of Dimebon.
Demographically comparable to subjects with mild and moderate hepatic impairment.
Subjects with hepatic impairment: Screening medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory tests performed within 28 days before the first dose of study medication, abnormal findings that are related to the subject's underlying condition are acceptable.
Satisfy the criteria for Class A, B, or C of the modified Child-Pugh classification [Mild (Child-Pugh Scores 5-6 points), moderate (Child-Pugh Scores 7-9 points), and severe (Child-Pugh Scores >9 and <12 points)] within 14 days before the first dose of study medication.
A diagnosis of hepatic impairment due to cirrhosis, not secondary to other diseases, which is confirmed and documented by medical history, physical examination, liver biopsy or hepatic ultrasound, CT scan or MRI.

Exclusion Criteria:

Subjects presenting with any of the following will not be included in the trial:CYP2D6 PM genotype, as identified by screening genotyping.
A known sensitivity to Dimebon.
Exposure within the previous three months to a drug known to have a negative effect on skeletal muscle or reproductive organs.
History of febrile illness within 5 days prior to the first dose.
Any condition possibly affecting drug absorption (e.g., gastrectomy, active peptic ulcer within last 3 months).

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00831532

Locations

United States, Florida
Pfizer Investigational Site
Orlando, Florida, United States, 32809
United States, Indiana
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46260

Sponsors and Collaborators

Pfizer

Medivation, Inc.

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Additional Information:

No publications provided

Responsible Party:	Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier:	NCT00831532 History of Changes
Other Study ID Numbers:	B1451018
Study First Received:	January 20, 2009
Last Updated:	September 14, 2009
Health Authority:	United States: Food and Drug Administration

Keywords provided by Pfizer:

Dimebon Hepatic Impairment

Additional relevant MeSH terms:

Liver Failure
Liver Diseases
Hepatic Insufficiency
Digestive System Diseases

ClinicalTrials.gov processed this record on October 18, 2012